Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

$ 20.78 -1.56 %

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL), along with its various subsidiaries, operates as a comprehensive pharmaceutical enterprise. It is actively engaged in the research, development, production, and distribution of a wide array of products, including traditional Chinese patent medicines, Western pharmaceuticals, chemical raw materials, natural and biological medications, and chemical raw material intermediates. Its operations span both the People's Republic of China and international markets. The company structures its extensive operations into four primary segments: Great Southern TCM, Great Commerce, Great Health, and a miscellaneous 'Others' category. Beyond its core pharmaceutical manufacturing, GBPHCL's activities extend to the wholesale, retail, import, and export of both Western and traditional Chinese medicines, as well as medical apparatus and instruments. Furthermore, its diverse product portfolio encompasses the research, development, production, and sale of consumer health items such as beverages, various food products (including pre-packaged items and dairy), and a broad range of pharmaceutical formulations like tablets, capsules, lozenges, injections, and even traditional specialties like tortoise herb jelly. The group also strategically invests in the broader health industry, focusing on areas like medical care, health management, health preservation, and elderly care. Complementing these activities, it offers commercial and advertising services. As of December 31, 2021, GBPHCL maintained a substantial retail presence, operating 154 chain pharmacy outlets. This network comprised 22 Cai Zhi Lin pharmacies, 36 Jian Min pharmacies, 51 GPC Prescription Pharmacy locations, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd. outlets, alongside an additional 22 general retail stores. Tracing its origins back to its incorporation in 1997, the company was initially known as Guangzhou Pharmaceutical Company Limited. It adopted its current name, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, in August 2013. The company is headquartered in Guangzhou, China.

CEO: Hong Li - https://www.gybys.com.cn

Price objectif

-

Recommandation

-

DCF

$ 11.31

Loading data...

600332.SS vs S&P500

Loading data...

No data available.

Quick ratio

1.29

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

11.48

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1.81

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

7.70 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

3.98 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

4.60

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.59

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.45

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

69.49 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
2.16 indicates an uncertain financial situation
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.30 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.26 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.